The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease
- PMID: 8055235
The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease
Abstract
Cholestasis results from either failure of bile formation or obstruction to bile flow. Liver diseases characterized by chronic cholestasis frequently cause progressive hepatocellular injury, cirrhosis, and death. Recent studies have shown that bile salts have an important role in the genesis and maintenance of liver injury in chronic cholestatic liver diseases. Ursodeoxycholic acid, a unique bile acid, protects the liver from injury by harmful bile acids and has been shown to improve symptoms and to delay the onset of liver failure and complications of cirrhosis. The rationale for its use and the results from clinical trials in chronic cholestasis are reviewed. Recommendations for the use of ursodeoxycholic acid in chronic cholestatic liver diseases are provided.
Similar articles
-
[Bile acids in liver diseases--current indications].Ther Umsch. 1995 Oct;52(10):682-6. Ther Umsch. 1995. PMID: 7482380 Review. German.
-
Ursodeoxycholic acid for the treatment of cholestatic diseases.Prog Liver Dis. 1992;10:219-38. Prog Liver Dis. 1992. PMID: 1296231 Review. No abstract available.
-
[Medical treatment of chronic cholestasis: ursodeoxycholic acid].Gastroenterol Hepatol. 2000 Feb;23 Suppl 1:24-38. Gastroenterol Hepatol. 2000. PMID: 11968340 Review. Spanish. No abstract available.
-
[Drug therapy of cholestatic hepatopathies].Schweiz Rundsch Med Prax. 1992 Aug 18;81(34):983-4. Schweiz Rundsch Med Prax. 1992. PMID: 1529191 German.
-
Therapy with ursodeoxycholic acid in cholestatic liver disease.Scand J Gastroenterol Suppl. 1993;200:15-20. doi: 10.3109/00365529309101569. Scand J Gastroenterol Suppl. 1993. PMID: 8016564 Review.
Cited by
-
Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats.PLoS One. 2014 Sep 9;9(9):e106993. doi: 10.1371/journal.pone.0106993. eCollection 2014. PLoS One. 2014. PMID: 25202970 Free PMC article.
-
[Cholestasis and liver dysfunction in critical care patients].Anaesthesist. 2008 Dec;57(12):1172-82. doi: 10.1007/s00101-008-1459-y. Anaesthesist. 2008. PMID: 18989650 Review. German.
-
Accelerating adverse pregnancy outcomes research amidst rising medication use: parallel retrospective cohort analyses for signal prioritization.BMC Med. 2024 Oct 25;22(1):495. doi: 10.1186/s12916-024-03717-0. BMC Med. 2024. PMID: 39456023 Free PMC article.
-
Management Of Primary Sclerosing Cholangitis.Gastroenterol Hepatol (N Y). 2006 Nov;2(11):843-849. Gastroenterol Hepatol (N Y). 2006. PMID: 28381955 Free PMC article.
-
Ursodeoxycholic Acid Protects Against Arsenic Induced Hepatotoxicity by the Nrf2 Signaling Pathway.Front Pharmacol. 2020 Oct 16;11:594496. doi: 10.3389/fphar.2020.594496. eCollection 2020. Front Pharmacol. 2020. PMID: 33178028 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical